

Press Release

IOL Chemicals and Pharmaceuticals Ltd reported highest ever revenue in Q3/9 Months' FY20

Dated: 10.02.2020

Place: Ludhiana


IOL Chemicals and Pharmaceuticals Limited a leading manufacturer of APIs / bulk drugs and specialty chemicals today posted remarkable operational and financial performance for the third quarter of financial year 2019-20.

Financial Highlights:

Particulars	Rs in crore							
	Q3 FY20 (i)	Q2 FY20 (ii)	Q3 FY19 (iii)	Change (i) v/s (ii)	Change (i) v/s (iii)	Nine Months FY 20	Nine Months FY 19	Change
Revenues	515	452	479	14%	8%	1464	1271	15%
EBITDA	163	136	136	20%	20%	448	261	72%
PAT	98	88	82	11%	19%	271	135	101%
EPS (Rs / Share)	17.22	15.42	14.63	12%	18%	47.64	24.03	98%


Quarter ended December 2019 v/s Quarter ended September 2019

- Income from operations increased by 14% to ₹ 515 crore from ₹ 452 crore.
- EBIDTA increased by 20% to ₹ 163 crore from ₹ 136 crore.
- Net Profit increased by 11% to ₹ 98 crore from ₹ 88 crore.
- EPS increased by 12% to ₹ 17.22 from ₹ 15.42.




Quarter ended December 2019 v/s Quarter ended December 2018

- Income from operations increased by 8% to ₹ 515 crore from ₹ 479 crore.
- EBITDA increased by 20% to ₹ 163 crore from ₹ 136 crore.
- Net Profit increased by 19% to ₹ 98 crore from ₹ 82 crore.
- EPS increased by 18% to ₹ 17.22 from ₹ 14.63.



Nine months ended December 2019 v/s Nine months ended December 2018

- Income from operations increased by 15% to ₹ 1464 crore from ₹ 1271 crore.
- EBITDA increased by 72% to ₹ 448 crore from ₹ 261 crore.
- Net Profit increased by 101% to ₹ 271 crore from ₹ 135 crore.
- EPS increased by 98% to ₹ 47.64 from ₹ 24.03.



Mr Vijay Garg, Joint Managing Director said “We are excited to report highest quarterly revenue ever and the company continued to repeat its strong operational and financial performance during the quarter ended 31st December 2019 also. We remain optimistic about growth in the demand of the Ibuprofen and recently launched new products in medium to long term and target to gain in the market with focused efforts to improve our sales and customer satisfaction.”

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986, listed on National Stock Exchange (Code: IOLCP) and Bombay Stock Exchange (Code: 524164) is one of the leading APIs/ bulk drugs Company and is significant player in the specialty chemicals space with world class facilities. IOLCP has wide presence across major therapeutic categories like, Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and anti-platelets.

IOLCP's product portfolio includes APIs; Ibuprofen, Metformin, Fenofibrate, Clopidogrel, Lamotrigine, Pantoprazole and specialty chemicals such as Ethyl Acetate, Iso Butyl Benzene, Mono Chloro Acetic Acid and Acetyl Chloride.

Company is World's largest producer of the Ibuprofen with an installed capacity of 12,000 TPA and having backward integrated manufacturing facility. The Company has DSIR approved R&D which is fully equipped to validate existing processes.

The Central and State Government approved Effluent Treatment Plant (ETP) had been set up with zero effluent discharge system alongwith 17 MW captive Co-Generation plant for self reliance. The Company is ISO 9001:2015, 14001:2015 and BS OHSAS 18001:2007 certified.

IOLCP's overseas customers are spread out across several countries including UK, Austria, Belgium, Hungary, Spain, Germany, Italy, Netherlands, Switzerland, Portugal, Poland, Ireland, USA, Australia, Chile, Peru, Brazil, Argentina, Colombia, Mexico, Indonesia, South Korea, Thailand etc. Products are sold primarily to Branded Generic formulators both in India & Overseas.

Disclaimer:

This document may contain statement which reflect management's current views and estimates and could be construed as forward looking statements. The future involves certain risks and uncertainties, and could cause actual results to differ materially for the current views being expressed. Potential risks and uncertainties include factors as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.